AWM
CTKB icon

AE Wealth Management’s Cytek Biosciences CTKB Stock Holding History

AE Wealth Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51K Sell
11,512
-2,681
-19% -$11.4K ﹤0.01% 2084
2026
Q1 		$62K Buy
+14,193
New +$67K ﹤0.01% 1915

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AE Wealth Management's CTKB Position: Q2 2026 in Review

AE Wealth Management reduced its Cytek Biosciences (CTKB) stake by 19% in Q2 2026, selling an estimated $11.4K and leaving 11,512 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #2084.

AE Wealth Management first reported a position in CTKB in Q1 2026 and has held it in 2 quarters since. The position peaked at $62K in Q1 2026. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • AE Wealth Management held 11,512 shares of Cytek Biosciences worth $51K as of Q2 2026.
  • AE Wealth Management sold 2,681 Cytek Biosciences shares in Q2 2026, an estimated $11.4K.
  • Cytek Biosciences made up ﹤0.01% of AE Wealth Management's portfolio in Q2 2026, its #2084 holding.
  • AE Wealth Management first reported a position in Cytek Biosciences in Q1 2026 and has held it in 2 quarters since.
  • AE Wealth Management's Cytek Biosciences position peaked at $62K in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on AE Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.